Is SUPERNUS PHARMACEUTICALS, INC. (SUPN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.1% / 30% | 14.7% / 30% | 4.6% / 30% | N/A | ✓ HALAL |
| DJIM | 1.1% / 33% | 14.7% / 33% | 4.6% / 33% | N/A | ✓ HALAL |
| MSCI | 2.5% / 33% | 33.2% / 33% | 10.4% / 33% | N/A | ✓ HALAL |
| S&P | 1.1% / 33% | 14.7% / 33% | 4.6% / 33% | N/A | ✓ HALAL |
| FTSE | 2.5% / 33% | 33.2% / 33% | 10.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 89.6% | |
| Operating Margin | -28.9% | |
| Net Margin | -5.4% | |
| Return on Equity (ROE) | -3.7% | |
| Return on Assets (ROA) | -2.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $47M |
| Free Cash Flow | $46M |
| Total Debt | $41M |
| Debt-to-Equity | 3.9 |
| Current Ratio | 1.9 |
| Total Assets | $1.5B |
Price & Trading
| Last Close | $50.80 |
| 50-Day MA | $50.98 |
| 200-Day MA | $45.56 |
| Avg Volume | 728K |
| Beta | 0.7 |
|
52-Week Range
$29.16
| |
About SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is SUPERNUS PHARMACEUTICALS, INC. (SUPN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), SUPERNUS PHARMACEUTICALS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is SUPERNUS PHARMACEUTICALS, INC.'s debt ratio?
SUPERNUS PHARMACEUTICALS, INC.'s debt ratio is 1.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.5%.
What are SUPERNUS PHARMACEUTICALS, INC.'s key financial metrics?
SUPERNUS PHARMACEUTICALS, INC. has a market capitalization of $2.9B, and revenue of $719M. The company maintains a gross margin of 89.6% and a net margin of -5.4%. Return on equity stands at -3.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.